Outcomes of GreenLight XPS-180W laser photovaporization for BPH larger than 80mL
Copyright © 2017 Elsevier Masson SAS. All rights reserved..
AIM: To evaluate the results of GreenLight XPS photovaporization (PVP/XPS) with intraoperative transrectal ultrasonographic monitoring for the treatment of large Benign Prostatic Hyperplasia (BPH) (>80mL).
PATIENTS AND METHODS: Operative and perioperative data of 82 patients were collected prospectively. Complications and functional outcomes (IPSS, quality of life (QoL) score, maximal flow rate and post-void residual (PVR)) were evaluated at 1, 3, 12 months post-operatively prostate volume and PSA were assessed at 3 and 12 months post-operatively.
RESULTS: Median patient age was 68.5years (50-85). Twenty percent had an indwelling catheter and 5%/22% were on anticoagulant/antiplatelet therapy. Median prostate volume and PSA were 103mL (80-220) and 6.4ng/mL (0.66-44.0). Median operative time and energy delivered were 107min (46-219) and 581kJ (212-1193). Energy delivered/prostate volume was 5.4kJ/mL (1.6-10.5). Transurethral catheter was removed at day 1 or 2 in 96% of cases. Patients were discharged as outpatient, p.o. day 1 or day 2 in 4%, 55% and 21% of cases, respectively. Transfusion and Clavien≥3 complication rates were 1.2% and 3.7%. Significant improvement of IPSS (4 vs 19.5), QoL (1 vs 5), maximum flow rate (19.1 vs 8.2mL/s) and PVR (26 vs 100mL) was observed (P<0.001) at 12-months evaluation. PSA and prostate volume were decreased by 61 and 62%. Late complications were urethral strictures (6%), stress incontinence (1.2%). Eighty-five percent of patients had no antegrade ejaculation.
CONCLUSION: The treatment of large BPH with PVP/XPS is safe and effective, with a long operative time. The functional outcomes are good and stable at mid-term evaluation.
LEVEL OF EVIDENCE: 4.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 27(2017), 8-9 vom: 01. Juni, Seite 489-496 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Résultats de la photovaporisation prostatique par laser GreenLight XPS-180W dans l’hyperplasie bénigne de prostate (HBP) de gros volume (≥80mL) |
|---|
| Beteiligte Personen: |
Thoulouzan, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.05.2018 Date Revised 30.05.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2017.04.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271687967 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271687967 | ||
| 003 | DE-627 | ||
| 005 | 20231224233243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2017.04.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271687967 | ||
| 035 | |a (NLM)28483481 | ||
| 035 | |a (PII)S1166-7087(17)30091-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Thoulouzan, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of GreenLight XPS-180W laser photovaporization for BPH larger than 80mL |
| 246 | 3 | 3 | |a Résultats de la photovaporisation prostatique par laser GreenLight XPS-180W dans l’hyperplasie bénigne de prostate (HBP) de gros volume (≥80mL) |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2018 | ||
| 500 | |a Date Revised 30.05.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a AIM: To evaluate the results of GreenLight XPS photovaporization (PVP/XPS) with intraoperative transrectal ultrasonographic monitoring for the treatment of large Benign Prostatic Hyperplasia (BPH) (>80mL) | ||
| 520 | |a PATIENTS AND METHODS: Operative and perioperative data of 82 patients were collected prospectively. Complications and functional outcomes (IPSS, quality of life (QoL) score, maximal flow rate and post-void residual (PVR)) were evaluated at 1, 3, 12 months post-operatively prostate volume and PSA were assessed at 3 and 12 months post-operatively | ||
| 520 | |a RESULTS: Median patient age was 68.5years (50-85). Twenty percent had an indwelling catheter and 5%/22% were on anticoagulant/antiplatelet therapy. Median prostate volume and PSA were 103mL (80-220) and 6.4ng/mL (0.66-44.0). Median operative time and energy delivered were 107min (46-219) and 581kJ (212-1193). Energy delivered/prostate volume was 5.4kJ/mL (1.6-10.5). Transurethral catheter was removed at day 1 or 2 in 96% of cases. Patients were discharged as outpatient, p.o. day 1 or day 2 in 4%, 55% and 21% of cases, respectively. Transfusion and Clavien≥3 complication rates were 1.2% and 3.7%. Significant improvement of IPSS (4 vs 19.5), QoL (1 vs 5), maximum flow rate (19.1 vs 8.2mL/s) and PVR (26 vs 100mL) was observed (P<0.001) at 12-months evaluation. PSA and prostate volume were decreased by 61 and 62%. Late complications were urethral strictures (6%), stress incontinence (1.2%). Eighty-five percent of patients had no antegrade ejaculation | ||
| 520 | |a CONCLUSION: The treatment of large BPH with PVP/XPS is safe and effective, with a long operative time. The functional outcomes are good and stable at mid-term evaluation | ||
| 520 | |a LEVEL OF EVIDENCE: 4 | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Benign prostatic hyperplasia | |
| 650 | 4 | |a Hyperplasie de la prostate | |
| 650 | 4 | |a Lasers | |
| 650 | 4 | |a Photovaporisation prostatique | |
| 650 | 4 | |a Prostate photovaporization | |
| 650 | 4 | |a Résultat thérapeutique | |
| 650 | 4 | |a Transrectal ultrasonography | |
| 650 | 4 | |a Treatment outcome | |
| 650 | 4 | |a Échographie endorectale | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 700 | 1 | |a Perrouin-Verbe, M-A |e verfasserin |4 aut | |
| 700 | 1 | |a Calves, J |e verfasserin |4 aut | |
| 700 | 1 | |a Deruelle, C |e verfasserin |4 aut | |
| 700 | 1 | |a Joulin, V |e verfasserin |4 aut | |
| 700 | 1 | |a Valeri, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 27(2017), 8-9 vom: 01. Juni, Seite 489-496 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2017 |g number:8-9 |g day:01 |g month:06 |g pages:489-496 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2017.04.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2017 |e 8-9 |b 01 |c 06 |h 489-496 | ||